Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
Deutsche Post AG
OTC:DPSTF
|
DE |
|
B
|
Boeing Co
XMUN:BCO
|
US |
|
R
|
Reach PLC
F:MRR
|
UK |
|
Morgan Stanley
NYSE:MS
|
US |
|
B
|
Baidu Inc
XMUN:B1CB
|
CN |
|
A
|
Abbott Laboratories
DUS:ABL
|
US |
|
S
|
SoftBank Group Corp
F:SFT
|
JP |
|
Frencken Group Ltd
SGX:E28
|
MY |
|
ST Group Food Industries Holdings Ltd
SGX:DRX
|
AU |
|
Toho Co Ltd (Tokyo)
OTC:TKCOF
|
JP |
|
E
|
Enterprise Metals Ltd
F:RM9
|
AU |
Intrinsic Value
Is RXRX undervalued or overvalued?
See the intrinsic value estimate for Recursion Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Recursion Pharmaceuticals Does
Recursion Pharmaceuticals is a drug discovery company that uses automation, large-scale biological experiments, and software to find new medicines faster. It builds a digital map of cells and uses that data to spot how diseases behave and which compounds might change them. The company mainly sells research partnerships and also develops its own drug candidates.
- Headquarters
- United States of America US
- Employees
- 600
- IPO date
- Apr 16, 2021
Recursion Pharmaceuticals has no economic moat
Recursion Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Recursion Pharmaceuticals Inc
The intrinsic value for Recursion Pharmaceuticals Inc (RXRX) under the Base Case is hidden USD.
Compared with the current market price of 3.475 USD, the stock appears hidden.
